Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Donadon, Matteo; Lopci, Egesta; Galvanin, Jacopo; Giudici, Simone; Fabbro, Daniele Del; Lanza, Ezio; Pedicini, Vittorio; Chiti, Arturo; Torzilli, Guido

doi:10.3390/cancers13030472

Cited by 5 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in its concentration should allow detection through different imaging modalities (45). Citrate metabolism in prostate cancer has been used as another marker of aggressiveness (44,45). The absence of significant difference in citrate concentration alone between groups in our study might be explained by the lack of power because of the small sample size.…”

Section: Discussionmentioning

confidence: 73%

“…The relationship between tumor aggressiveness and increased choline metabolism has already been studied in a number of series. The correlation is readily accepted and the use in routine of 11 C-Choline PET in the study of prostate cancer as well as hepatocellular carcinoma (44,45). As for the physiopathological explication, choline is involved in the lipid metabolism notably membrane, but also as a methyl donor.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T

Deal¹,

Bardet²,

Walker³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: The limitations of the assessment of tumor aggressiveness by Prostate Imaging Reporting and Data System (PI-RADS) and biopsies suggest that the diagnostic algorithm could be improved by quantitative measurements in some chosen indications. We assessed the tumor high-risk predictive performance of 3.0 Tesla (3.0T) multiparametric magnetic resonance imaging (mp-MRI) combined with nuclear magnetic resonance spectroscopic sequences (NMR-S) in order to show that the metabolic analysis could bring out an evocative result for the aggressive form of prostate cancer. Methods:We conducted a retrospective study of 26 patients (mean age, 62.4 years) who had surgery for prostate cancer between 2009 and 2016 after pre-therapeutic assessment with 3.0T mp-MRI and NMR-S.Groups within the intermediate range of the D'Amico risk classification were divided into two categories, low risk (n=20) and high risk (n=6), according to the International Society of Urological Pathology (ISUP) 2-3 limit. Histoprognostic discordances within various risk groups were compared with the corresponding predictive MRI values. The performance of predictive models was assessed based on sensitivity, specificity, and the area under the curve (AUC) of receiver operating characteristic (ROC) curves.Results: After prostatectomy, histological analysis reclassified 18 patients as high-risk, including 16 who were T3 MRI grade, of whom 13 (81.3%) were found to be pT3. Among the patients who had cT1 or cT2 digital rectal examinations, the T3 MRI factor multiplied by 8.7 [odds ratio (OR), 8.7; 95% confidence interval (CI), 1.3-56.2; P=0.024] the relative risk of being pT3 and by 5.8 (OR, 5.8; 95% CI, 0.95-35.7; P=0.05) the relative risk of being pGleason (pGS) > GS-prostate biopsy. Spectroscopic data showed that the choline concentration was significantly higher (P=0.001) in aggressive disease. Conclusions:The predictive model of tumor aggressiveness combining mp-MRI plus NMR-S was better than the mp-MRI model alone (AUC, 0.95 vs. 0.86). Information obtained by mp-MRI coupled with spectroscopy may improve the detection of occult aggressive disease, helping in the discrimination of intermediate risks.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 98%

Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T

Deal¹,

Bardet²,

Walker³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

show abstract

“…Choline PET is being explored for use in hepatocellular carcinomas 248 and in hyperparathyroidism. 249 Hepatocellular carcinoma is slow growing and, like prostate cancer, does not avidly take up FDG for PET scanning.…”

Section: Future Trends In Phospholipid Research and Cancermentioning

confidence: 99%

History of Research on Phospholipid Metabolism and Applications to the Detection, Diagnosis, and Treatment of Cancer

Cohen

Daly

2022

Substantia

View full text Add to dashboard Cite

In the past 30 years there has been a significant increase in the number of publications on phospholipid (PL) metabolism, both for the medical purposes of detection and diagnosis of cancer and for the monitoring of the treatment of human cancers. Most of the work has focused on the pathway that produces phosphatidylcholine, the major component of human cell membranes. The trigger for this research was the advent of applications of NMR spectroscopy in vitro and in vivo in the 1980’s and observations that most cancer cells and tumors had significant increases in the water-soluble PL precursors and breakdown products. Increased phosphocholine (PC) has been focused on as a marker for cancer using Magnetic Resonance Spectroscopy (MRS) and Positron Emission Tomography (PET). MRS is now used clinically to aid in the diagnosis and severity of some brain tumors; and choline PET is used for the diagnosis and staging of recurrent prostate cancer, paid for by medical insurance companies. Another major area of research starting in the 1990’s was the development of specific choline kinase (CK) inhibitors aimed at the isoenzyme CK-a. This isoenzyme is markedly upregulated in cancer cells and unexpectedly was found to have a role in oncogenic transformation independent of its enzyme function.

show abstract

Anatomical liver resection using the ultrasound-guided compression technique in minimal access surgery

Procopio,

Branciforte,

Galvanin

et al. 2023

Surg Endosc

View full text Add to dashboard Cite

Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Cited by 5 publications

References 38 publications

Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T

Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T

History of Research on Phospholipid Metabolism and Applications to the Detection, Diagnosis, and Treatment of Cancer

Anatomical liver resection using the ultrasound-guided compression technique in minimal access surgery

Contact Info

Product

Resources

About